Patents by Inventor Edward A. Kesicki

Edward A. Kesicki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230017140
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 2, 2022
    Publication date: January 19, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. Boyles, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Alfredo PICADO, Gerit Maria POTOTSCHNIG, Michael Brian WELCH, Tien WIDJAJA, Xiaohong CHEN, Nathan Edward WRIGHT, Hua-Yu WANG
  • Publication number: 20230014445
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 2, 2022
    Publication date: January 19, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Xiaohong CHEN, Surendra DAWADI, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Gabrielle R. KOLAKOWSKI, Jennifer Lynn KNIGHT, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Alfredo PICADO, Gerit Maria POTOTSCHNIG, Hua-Yu WANG, Michael Brian WELCH, Tien WIDJAJA, Nathan Edward WRIGHT
  • Patent number: 11535635
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 27, 2022
    Assignee: HiberCell, Inc.
    Inventors: Johan Lindström, Lars Boukharta Persson, Jenny Viklund, Rickard Forsblom, Tobias Ginman, Edward A. Kesicki, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto
  • Publication number: 20220372046
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.
    Type: Application
    Filed: January 14, 2022
    Publication date: November 24, 2022
    Inventor: Edward A. Kesicki
  • Publication number: 20220372023
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Application
    Filed: April 2, 2021
    Publication date: November 24, 2022
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Markus K. DAHLGREN, Shulu FENG, Aleksey I. GERASYUTO, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Anke KLIPPEL-GIESE, Jennifer Lynn KNIGHT, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, David L. MCELLIGOTT, Johnathan Alexander MCLEAN, Loredana PUCA, Kannan Karukurichi RAVI, Daniel Lee SEVERANCE, Michael Brian WELCH, Tien WIDJAJA
  • Patent number: 11498929
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: November 15, 2022
    Assignee: HiberCell, Inc.
    Inventor: Edward A. Kesicki
  • Publication number: 20210332047
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: November 24, 2020
    Publication date: October 28, 2021
    Inventors: Edward A. KESICKI, Kerry W. FOWLER, Danwen HUANG, Hua Chee OOI, Amy OLIVER, Kamal Deep PURI, Fuqiang RUAN, Jennifer TREIBERG
  • Publication number: 20210317136
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 14, 2021
    Inventors: Johan LINDSTRÖM, Lars Boukharta PERSSON, Jenny VIKLUND, Edward A. KESICKI, Eugene R. HICKEY, Markus K. DAHLGREN, Aleksey I. GERASYUTO
  • Publication number: 20210253600
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.
    Type: Application
    Filed: December 21, 2018
    Publication date: August 19, 2021
    Inventors: Johan LINDSTRÖM, Lars Boukharta PERSSON, Jenny VIKLUND, Rickard FORSBLOM, Tobias GINMAN, Edward A. KESICKI, Eugene R. HICKEY, Markus K. DAHLGREN, Aleksey I. GERASYUTO
  • Patent number: 10906907
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of preparing such compounds are also disclosed, including the preparation and use of the compound tert-butyl (S)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate of formula (110) as a precursor to synthesize an exemplary compound disclosed in this application, (S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: February 2, 2021
    Assignee: ICOS CORPORATION
    Inventors: Edward A. Kesicki, Kerry W. Fowler, Danwen Huang, Hua Chee Ooi, Amy Oliver, Kamal Deep Puri, Fuqiang Ruan, Jennifer A. Treiberg
  • Publication number: 20200392156
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.
    Type: Application
    Filed: June 17, 2020
    Publication date: December 17, 2020
    Inventor: Edward A. KESICKI
  • Publication number: 20200392162
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.
    Type: Application
    Filed: June 17, 2020
    Publication date: December 17, 2020
    Inventor: Edward A. KESICKI
  • Publication number: 20200331913
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 22, 2020
    Inventors: Johan LINDSTRÖM, Lars Boukharta PERSSON, Madeleine LIVENDAHL, Jenny VIKLUND, Tobias GINMAN, Rickard FORSBLOM, Fredrik RAHM, Edward A. KESICKI, Kannan Karukurichi RAVI, Eugene R. HICKEY, Markus K. DAHLGREN, Aleksey I. GERASYUTO
  • Patent number: 10695349
    Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K? plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K?, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity. Methods of using PI3K? inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K? inhibitory compounds to inhibit PI3K?-mediated processes in vitro and in vivo.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: June 30, 2020
    Assignee: ICOS Corporation
    Inventors: Chanchal Sadhu, Ken Dick, Jennifer Treiberg, C. Gregory Sowell, Edward A. Kesicki, Amy Oliver
  • Publication number: 20200179357
    Abstract: Stable, clear, ophthalmic formulations and methods of use for an opthalmologically therapeutic effective amount of a TRPA1 antagonist, the formulation comprising buffer system, a viscosity enhancing agent, optionally a preservative, with an opthalmologically acceptable osmolarity and pH, all in an aqueous vehicle. These formulations are effective for treating ocular diseases or conditions caused by, or associated with, or accompanied by ocular pain and inflammatory processes, including, among others, dry eye N disease, uveitis, or any trauma caused by eye surgery or eye injury.
    Type: Application
    Filed: July 6, 2017
    Publication date: June 11, 2020
    Inventors: Jeffrey M. HERZ, Edward A. KESICKI, Charles P. ZUTA
  • Publication number: 20200061062
    Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K? plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K?, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity. Methods of using PI3K? inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K? inhibitory compounds to inhibit PI3K?-mediated processes in vitro and in vivo.
    Type: Application
    Filed: August 1, 2019
    Publication date: February 27, 2020
    Inventors: Chanchal SADHU, Ken DICK, Jennifer TREIBERG, C. Gregory SOWELL, Edward A. KESICKI, Amy OLIVER
  • Publication number: 20200017503
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Application
    Filed: May 21, 2019
    Publication date: January 16, 2020
    Inventors: Edward A. KESICKI, Kerry W. FOWLER, Danwen HUANG, Hua Chee OOI, Amy OLIVER, Kamal Deep PURI, Fuqiang RUAN, Jennifer A. TREIBERG
  • Patent number: 10428049
    Abstract: This disclosure relates to polycyclic heteroaromatic compounds useful as TRPA1 modulators, as well as compositions and methods of treating pain that include the compounds.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: October 1, 2019
    Assignee: ALGOMEDIX, INC.
    Inventors: Jeffrey M. Herz, Edward A. Kesicki
  • Patent number: 10398695
    Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K? plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K?, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity. Methods of using PI3K? inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K? inhibitory compounds to inhibit PI3K?-mediated processes in vitro and in vivo.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: September 3, 2019
    Assignee: ICOS CORPORATION
    Inventors: Chanchal Sadhu, Ken Dick, Jennifer Treiberg, C. Gregory Sowell, Edward A. Kesicki, Amy Oliver
  • Patent number: 10336756
    Abstract: Compounds that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity, are disclosed. Methods of preparing such compounds are also disclosed, including the use of (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one as a precursor to synthesize an exemplary compound disclosed in this application, (S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K? plays a role in leukocyte function, using the compounds also are disclosed.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: July 2, 2019
    Assignee: ICOS CORPORATION
    Inventors: Edward A. Kesicki, Kerry W. Fowler, Danwen Huang, Hua Chee Ooi, Amy Oliver, Kamal Deep Puri, Fuqiang Ruan, Jennifer Treiberg